Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.43 |
| ▸ | RAB9A | P51151 | 6/20 | 0.43 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | LTA4H | P09960 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10719025 | 0.78 | ALDH1A1 (0.61) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL87533 | 0.75 | — | — | |
| SCHEMBL28232834 | 0.73 | NPC1 (0.31) | NPC1RAB9AMAPTHSD17B10CYP3A4 | |
| SCHEMBL10857650 | 0.72 | ALDH1A1 (0.33) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL1422429 | 0.67 | KMT2A (0.39) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL23457475 | 0.67 | KDM4E (0.50) | NPC1RAB9AKDM4EMEN1KMT2A | |
| SCHEMBL13995930 | 0.66 | MAPT (0.48) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL17907394 | 0.66 | KDM4E (0.39) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL594201 | 0.65 | PRKACA (0.47) | ALDH1A1KDM4ECYP1A2 | |
| SCHEMBL1771825 | 0.64 | ALDH1A1 (0.79) | NPC1RAB9AMAPTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102584813-B | Compound and the purposes in regulating amyloid beta thereof | NGC药物公司 | 2016-07-06 | — | — | CN | disclosed |
| EP-1628666-B1 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS INC (US) | 2015-09-23 | — | — | EP | disclosed |
| CN-102584813-A | Compouds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS INC | 2012-07-18 | — | — | CN | disclosed |
| US-8119680-B2 | α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8017629-B2 | Compounds and uses thereof in modulating amyloid β | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20100331551-A1 | ALPHA-HALOKETONE DERIVATIVES OF IMIDAZOLYL-SUBSTITUTED AROMATIC COMPOUNDS AND COMPOUNDS PREPARED THEREFROM | NEUROGENETIC PHARMACEUTICALS, INC | 2010-12-30 | — | — | US | disclosed |
| US-20100324032-A1 | COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA | NEUROGENETIC PHARMACEUTICALS, INC. | 2010-12-23 | — | — | US | disclosed |
| US-7799808-B2 | α-Haloketone derivatives of imidazolyl-substituted aromatic compounds and compounds prepared therefrom | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7781442-B2 | Compounds and uses thereof in modulating amyloid beta | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| EP-1628666-A4 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | TORREYPINES THERAPEUTICS INC (US) | 2007-12-05 | — | — | EP | disclosed |
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | TORREYPINES THERAPEUTICS INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | TORREYPINES THERAPEUTICS INC. | 2007-10-25 | — | — | US | disclosed |
| US-7244739-B2 | Compounds and uses thereof in modulating amyloid beta | TORREYPINES THERAPEUTICS, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| CN-1787822-A | Compounds and their use in modulating amyloid beta | TORREYPINES THERAPEUTICS INC (US) | 2006-06-14 | — | — | CN | disclosed |
| EP-1628666-A2 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | Torreypines Therapeutics, Inc. (US) | 2006-03-01 | — | — | EP | disclosed |
| US-20050070538-A1 | Compounds and uses thereof in modulating amyloid beta | SIROCCO THERAPEUTICS, INC. | 2005-03-31 | — | — | US | disclosed |
| WO-2004110350-A2 | COMPOUDS AND USES THEREOF IN MODULATING AMYLOID BETA | TORREYPINES THERAPEUTICS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324032-A1 | COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA | APP, BACE1, BACE2 | NPC1 61/4885RAB9A 2158/4885MAPT 10/4885 |
| US-20070260058-A1 | Compounds and Uses Thereof in Modulating Amyloid Beta | APP, BACE1, BACE2 | NPC1 61/4885RAB9A 2158/4885MAPT 10/4885 |
| US-20050070538-A1 | Compounds and uses thereof in modulating amyloid beta | APP, BACE1, BACE2 | NPC1 61/4885RAB9A 2158/4885MAPT 10/4885 |
| US-20100331551-A1 | ALPHA-HALOKETONE DERIVATIVES OF IMIDAZOLYL-SUBSTITUTED AROMATIC COMPOUNDS AND COMPOUNDS PREPARED THEREFROM | HYPK, APP, NEFM | NPC1 229/4885RAB9A 3673/4885MAPT 7/4885 |
| US-20070249833-A1 | such as 2-bromo-1-[6-(4-methyl-imidazole-1-yl)-pyridin-3-yl]-ethanone, which have activity in modulating levels of amyloid-beta, useful in the treatment of neurodegenerative diseases, such as Alzheimer's disease | PSEN2, APP, BACE1 | NPC1 719/4885RAB9A 2805/4885MAPT 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.